Shares of Acorda Therapeutics (ACOR +4.2%) are higher in morning trading after the company provided preliminary financial results in connection with the JPMorgan Healthcare Conference.
Q4 and FY Ampyra net sales: $84M and $302M, respectively.
2014 Ampyra net sales guidance: $328-335M.
2014 opex guidance: R&D, $60-70M; SG&A, $180-190M.
2014 Zanaflex guidance and ex-U.S. Fampyra revenue: $25M